Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Unrealistic Optimism Bias01:30

Unrealistic Optimism Bias

Unrealistic optimism bias is the tendency to overestimate the likelihood of positive outcomes. This cognitive bias makes individuals believe they are less likely to experience failures, setbacks, or risks and more likely to succeed than others. For example, people may assume they are less prone to health issues, accidents, or financial struggles than their peers, even when they share similar risk factors.One key component of this bias is the above-average effect, where individuals perceive...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is tremelimumab beneficial in advanced melanoma?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2013
Same author

Guidelines for health technologies: specific guidance for oncology products in Canada.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2012
Same author

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.

Lung cancer (Amsterdam, Netherlands)·2012
Same author

Adjuvant interferon alfa for melanoma.

Current oncology (Toronto, Ont.)·2010
Same author

Impact on patient satisfaction with a structured counselling approach on natural health products.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2008
Same author

Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.

Cancer investigation·2007
Same journal

The use of natural language processing in predictive toxicology.

Expert opinion on drug metabolism & toxicology·2026
Same journal

An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens.

Expert opinion on drug metabolism & toxicology·2026
Same journal

Optimizing tamoxifen therapy in breast cancer: a narrative review of dose escalation in patients with CYP2D6 polymorphisms.

Expert opinion on drug metabolism & toxicology·2026
Same journal

Effect of concomitant rifampin and clarithromycin on elexacaftor-tezacaftor-ivacaftor using a physiologically based pharmacokinetic (PBPK) modeling approach.

Expert opinion on drug metabolism & toxicology·2026
Same journal

Gastrointestinal bleeding risk among antithrombotics users: a propensity score matched study of drug classes.

Expert opinion on drug metabolism & toxicology·2026
Same journal

Complex <i>in vitro</i> model developers' perspective on advanced hepatic <i>in vitro</i> culture methods for predictive drug safety.

Expert opinion on drug metabolism & toxicology·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Raltitrexed: optimism and reality.

Kenneth S Wilson1, Suzanne C Malfair Taylor

  • 1Vancouver Island Centre, Department of Medicine, Victoria, British Columbia, Canada. KWilson@bccancer.bc.ca

Expert Opinion on Drug Metabolism & Toxicology
|October 30, 2009
PubMed
Summary
This summary is machine-generated.

Raltitrexed showed similar efficacy to 5-fluorouracil (5-FU) in metastatic colorectal cancer (MCRC) but had higher treatment-related mortality. Its use is now limited due to safety concerns and evolving treatment landscapes.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Jun 19, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Raltitrexed, a thymidylate synthase inhibitor, was developed for metastatic colorectal cancer (MCRC).
  • Early trials indicated comparable efficacy to 5-fluorouracil (5-FU) in MCRC treatment.

Purpose of the Study:

  • To review pharmacokinetic data and Phase III trial results of raltitrexed.
  • To compare raltitrexed with 5-FU in adjuvant and MCRC settings.

Main Methods:

  • Pharmacokinetic analysis.
  • Review of Phase III adjuvant and metastatic colorectal cancer (MCRC) clinical trials for raltitrexed.

Main Results:

  • Raltitrexed demonstrated equivalent response rates and overall survival to 5-FU in MCRC.
  • Relapse-free survival was marginally longer with 5-FU. Raltitrexed showed favorable Grade 3+ toxicity but higher treatment-related mortality (TRM), often due to protocol violations.
  • Higher TRM in an adjuvant trial led to its discontinuation; overall survival remained similar to 5-FU despite excess TRM.

Conclusions:

  • Raltitrexed's simple regimen did not meet expectations, with limited space in current MCRC management.
  • Lack of sponsor support hinders further investigation compared to 5-FU.
  • Raltitrexed use in Canada is restricted to patients intolerant to 5-FU due to mucosal, hematological, or cardiac issues.